市場調查報告書

全球綠色膿菌感染疾病治療市場:成長,趨勢,及預測

Pseudomonas Aeruginosa Infection Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 922065
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
全球綠色膿菌感染疾病治療市場:成長,趨勢,及預測 Pseudomonas Aeruginosa Infection Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 112 Pages
簡介

本報告提供全球綠色膿菌感染疾病治療市場的相關調查,市場機會和趨勢,成長及阻礙因素,各治療、給藥途徑、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 院內感染疾病盛行率的增加
    • 綠色膿菌的研究與藥物研發的投資
  • 市場阻礙因素
    • 綠色膿菌的藥物抗性能力
  • 波特的五力分析

第5章 市場區隔

  • 各治療
    • 單劑療法
    • 聯合治療
  • 各給藥途徑
    • 經鼻
    • 口服
    • 經靜脈
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Allergan
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer, Inc.
    • Lupin Pharmaceuticals, Inc.
    • AstraZeneca
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Co.
    • Johnson & Johnson

第7章 市場機會及今後趨勢

目錄
Product Code: 67608

Market Overview

Pseudomonas Aeruginosa is a common encapsulated, Gram-negative, rod-shaped bacterium that can cause disease in humans. P. aeruginosa is a multidrug-resistant pathogen recognized for its ubiquity, its intrinsically advanced antibiotic resistance mechanisms, and its association with serious illnesses including hospital-acquired infections such as ventilator-associated pneumonia and various sepsis syndromes.

The prevalence of Hospital Acquired Infections has increased in recent years. As pseudomonas aeruginosa infection is one of the common infections in a hospital facility, the probability of being diagnosed with Pseudomonas Aeruginosa infection is high. This has led an increase in research and development in understanding P. aeruginosa. As a result, many drugs are in pipeline for the treatment of this infection. These factors have helped the growth of the market and are expected to help in the future as well.

However, as stated earlier, P. aeruginosa shows the ability of drug resistance. As a result, many drug developers, who have limited funds are dissuaded from the market. This factor has been hindering the market growth.

Scope of the Report

Pseudomonas Aeruginosa Infection Treatment Drugs inhibit the growth of pseudomonas aeruginosa or completely eliminate the bacterium.

In the report, a detailed analysis of the Pseudomonas Aeruginosa Infection Treatment market is provided. The market is evaluated by collating revenues generated across segments, categorized by Treatment, Route of Administration and Geography.

Key Market Trends

Combination Therapy is Expected to Dominate the Market

Combination therapy for the treatment of P. aeruginosa is administered due to different considerations. First, to cover the known or suspected pathogen while results of identification and susceptibility testing are pending, second, to avoid the emergence of resistance during treatment and third, due to possible synergistic activity resulting in better clinical outcome.

The research was published by Nicole Fosse et al., in PLoS One Journal 2018. During the study period, patients with P. aeruginosa bloodstream infections (BSI) were identified. Combination therapy was administered in 42.8% and the remaining 57.2% were treated with monotherapy. The research concluded that mortality was lower in patients receiving definite combination therapy, as compared to monotherapy and combination therapy showed good results.

Due to the benefits of combination therapy over monotherapy, this market is expected to increase in the forecast period.

North America is Expected to Dominate the Market

As per a report by the Agency for Healthcare Research and Quality, 2019, approximately 1 of every 25 hospitalized patients in the United States have a hospital-acquired infection (HAI). This ratio translated to nearly 650,000 patients contract one of these infections annually. According to the American Association for the Advancement of Science, proportion of patients with a hospital-acquired infection was 7.9% in 2017, in Canadian Hospitals. As pseudomonas aeruginosa infection is common, the probability of this infection is still prevalent in these countries.

However, the United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development. These policies encourage global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players. As high and increasing demand is met by the presence of global players in the region, the market is further expected to increase.

Competitive Landscape

The majority of the Pseudomonas Aeruginosa Infection Treatment drugs and therapies are being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market grow.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Hospital Acquired Infections
    • 4.2.2 Investment in Research and Drug Discovery for Pseudomonas Aeruginosa
  • 4.3 Market Restraints
    • 4.3.1 Drug Resistance Ability of Pseudomonas Aeruginosa
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment
    • 5.1.1 Monotherapy
    • 5.1.2 Combination Therapy
  • 5.2 By Route of Administration
    • 5.2.1 Nasal
    • 5.2.2 Oral
    • 5.2.3 Intravenous
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Allergan
    • 6.1.2 Teva Pharmaceutical Industries Ltd.
    • 6.1.3 Pfizer, Inc.
    • 6.1.4 Lupin Pharmaceuticals, Inc.
    • 6.1.5 AstraZeneca
    • 6.1.6 Merck & Co., Inc.
    • 6.1.7 Bristol-Myers Squibb Co.
    • 6.1.8 Johnson & Johnson

7 MARKET OPPORTUNITIES AND FUTURE TRENDS